Pharmacokinetics of moxisylyte in healthy volunteers after intravenous infusion and intracavernous administration with and without a penile tourniquet

Therapeutic Drug Monitoring

Volumn 18, Issue 2, 1996, Pages 135-144

  Costa, P ^a   Bressolle, F ^b,d   Mottet, N ^b   Rouzier Panis, R ^c   Navratil, H ^b   Marquer, C ^e  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b DEPARTMENT OF NEUROLOGY   (France)

^c Hopital Gaston Doumergue   (France)

^d UNIV MONTPELLIER   (France)

^e Laboratoires Debat   (France)

Author keywords

Healthy volunteers; Intracavernous; Intravenous; Moxisylyte; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; MOXISYLYTE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEACETYLMOXISYLYTE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; INTRACAVERNOUS DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PENIS; PENIS ERECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOURNIQUET;

ADULT; ANALYSIS OF VARIANCE; CROSS-OVER STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MOXISYLYTE; PENILE ERECTION; TOURNIQUETS; VASODILATOR AGENTS;

EID: 0029864673     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199604000-00005     Document Type: Article

References (37)

1. Krane RJ, Goldstein I, Saenz de Tejada I. Medical progress. Impotence. N Engl J Med 1989;321:1649-59.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
3. Brindley GS. Cavernosal alpha-blockade: a new technique for investigating and treating impotence. Br J Psychiatry 1983;143:332-7.
4. Bodner DR, Lindan R, Leffler E, Kursh ED, Besnick ML. The application of intracavernous injection of vasoactive medications for erection in men with spinal cord injury. J Urol 1987;138:310-2.
5. Virag R. Intracavernous injections of papaverine for erectile failure [Letter]. Lancet 1982;2:938.
6. Brindley GS. Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis. Br J Pharmacol 1986;87:495-500.
7. Watters GR, Keogh EJ, Earle CM, et al. Experience in the management of erectile dysfunction using the intracavernosal self-injection of vasoactive drugs. J Urol 1988;140: 1417-9.
8. 1 and visual sexual stimulation. J Urol 1993;149:49-52.
9. 1 dose-response study in man. J Urol 1993;150:1825-8.
10. Buvat J, Lemaire A, Buvat-Herbaut M, Marcolin G. Safety of intracavernous injections using an alpha-blocking agent. J Urol 1989;141:1364-7.
11. Buvat J, Buvat-Herbaut M, Lemaire A, Marcolin G. Reduced rate of fibrotic nodules of the cavernous bodies following auto-intracavernous injection of moxisylyte compared to papaverine. Int J Impotence Res 1991;3:123-8.
12. Costa P, Sarrazin B, Bressolle F, Colson MH, Bondil P, Saudubray F. Efficiency and side-effects of intracavernous injections of moxisylyte in impotent patients: a dose-finding study versus placebo. J Urol 1993;149:301-5.
13. Govier FE, McClure RD, Weissman RM, Gibbons RP, Pritchett TR, Kramer-Levien D. Experience with triple-drug therapy in a pharmacological erection program. J Urol 1993; 150:1822-4.
14. Tanaka T. Papaverine hydrochloride in peripheral blood and the degree of penile erection. J Urol 1990;143:1135-7.
15. Costa P, Bressolle F, Sarrazin B, Mosser J, Navratil H, Galtier M. Moxisylyte plasma kinetics in humans after intracavernous administration. Biopharm Drug Dispos 1992; 13:671-9.
16. Costa P, Bressolle F, Sarrazin B, Mosser J, Galtier M. Pharmacokinetics of moxisylyte in healthy volunteers after intravenous and intracavernous administration. J Pharm Sci 1993;82:729-33.
17. Costa P, Soulie-Vassal ML, Sarrazin B, Rebillard X, Navratil H, Bali JP. Adrenergic receptors on smooth muscle cells isolated from human penile corpus cavernosum. J Urol 1993; 150:859-63.
18. Birmingham AT, Szolcsanyi J. Competitive blockade of adrenergic alpha-receptors and histamine receptors by thymoxamine. J Pharm Pharmacol 1965;17:449-58.
19. Mosler W. Die Behandlung der hypertensive Spattoxikosc mit opilon. Dtsch Ges Wes 1960;15:1221-5.
20. Duchene P, Bernouillet C, Bromet-Petit M, et al. Metabolism of 14C-thymoxamine in rat and man. Xenobiotica 1988; 18:919-28.
21. 14C-thymoxamine in man. Eur J Drug Metab Pharmacokinet 1985;10:71-6.
22. Marquer C, Trouvin JH, Lacolle JY, Dupont Ch, Jacquot C. Pharmacokinetics of a prodrug thymoxamine: dose-dependence of the metabolite ratio in healthy subjects. Eur J Drug Metab Pharmacokinet 1991;16:183-8.
23. Costa P, Bressolle F, Bromet-Petit M, Mosser J, Sarrazin B. Pharmacokinetics of moxisylyte in healthy volunteers after intravenous and oral administration. J Pharm Sci 1992;81: 1223-5.
24. Costa P, Bressolle F, Jarroux E, et al. Multiple-dose pharmacokinetics of moxisylyte after oral administration to healthy volunteers. J Pharm Sci 1993;82:968-71.
25. Nielsen-Kudsk F, Jakobsen P, Magnussen I. Plasma induced biotransformation of thymoxamine and its kinetics. Acta Pharmacol Toxicol 1980;47:11-6.
26. 14C-thymoxamine in rats. Eur J Drug Metab Pharmacokinet 1985;10:61-9.
27. Vollmer KO, von Hodenberg A. Metabolism of thymoxamine. III: structure elucidation of the metabolites and interspecies comparison. Eur J Drug Metab Pharmacokinet 1985;10:139-45.
28. Feniou C, Neau B, Prat G, Cheze C, Fauran F, Roquebert J. Metabolism of thymoxamine: identification of metabolites in rat. J Pharm Pharmacol 1980;32:104-7.
29. Russel RM, McGandy RB, Jelliffe D. Reference weight practical considerations. Am J Med 1984;76:767-9.
30. Gomeni C, Gomeni R. SIPHAR: an integrated computer system for statistical and pharmacokinetic data analysis. In: Serio A, O'Moore R, Tardini A, Roger FH, eds. Proceedings of the 7th International Congress of Medical Informatics. Rome: European Federation for Medical Informatics, 1987:507-16.
31. Taburet AM, Steimer JL, Doucet D, Singlas E. Le temps de présence moyen dans l'organisme: un nouveau paramètre pharmacocinétique. Therapie 1986;41:1-10.
32. Mandallas D, Mau J. Comparison of different methods for decision-making in bioequivalence assessment. Biometrics 1981;37:213-22.
33. Koch CG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972;28:577-84.
34. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990;28:72-8.
35. Westlake WJ. Symmetrical confidence intervals for bioequivalence trials. Biometrics 1976;32:741-4.
36. SAS Institute Inc. SAS user's guide: statistics. 5th ed. Cary: SAS Institute, 1985.
37. Hakenberg O, Wetterauer U, Koppermann U, Lünhman R. Systemic pharmacokinetics of papaverine and phentolamine: comparison of intravenous and intracavernous application. Int J Impotence Res 1990;2:S2247-8.